Antiplatelet Therapy in Diabetes

Arjun Majithia; Deepak L Bhatt

doi:10.1016/j.ecl.2017.10.009

Antiplatelet Therapy in Diabetes

Endocrinol Metab Clin North Am. 2018 Mar;47(1):223-235. doi: 10.1016/j.ecl.2017.10.009. Epub 2017 Dec 1.

Authors

Arjun Majithia¹, Deepak L Bhatt²

Affiliations

¹ Division of Cardiovascular Medicine, Lahey Hospital and Medical Center, 41 Burlington Mall Road, Burlington, MA 01805, USA.
² Division of Cardiovascular Medicine, Brigham and Women's Hospital Heart and Vascular Center and Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA. Electronic address: dlbhattmd@post.harvard.edu.

PMID: 29407053
DOI: 10.1016/j.ecl.2017.10.009

Abstract

Cardiovascular disease (CVD) is a significant cause of morbidity and mortality among patients with diabetes mellitus (DM). Increased platelet reactivity among patients with DM contributes to disproportionately high levels of atherothrombotic CVD. Consequently, there has been tremendous interest in exploring the role of antiplatelet therapies in DM to reduce the development of and frequency of future cardiovascular events.

Keywords: Antiplatelet therapy; Antithrombotic therapy; Cardiovascular disease; Diabetes; Thrombosis.

Publication types

Review

MeSH terms

Aspirin / pharmacology*
Cardiovascular Diseases* / drug therapy
Cardiovascular Diseases* / prevention & control
Diabetes Complications* / drug therapy
Diabetes Complications* / prevention & control
Humans
Platelet Aggregation Inhibitors / pharmacology*

Substances

Platelet Aggregation Inhibitors
Aspirin